Your browser is no longer supported. Please, upgrade your browser.
AZN AstraZeneca PLC daily Stock Chart
AZN [NYSE]
AstraZeneca PLC
Index- P/E52.69 EPS (ttm)0.86 Insider Own0.50% Shs Outstand2.62B Perf Week3.67%
Market Cap119.09B Forward P/E22.80 EPS next Y1.99 Insider Trans0.00% Shs Float2.61B Perf Month11.93%
Income2.19B PEG3.29 EPS next Q0.42 Inst Own18.70% Short Float0.55% Perf Quarter17.64%
Sales23.07B P/S5.16 EPS this Y-9.60% Inst Trans-2.74% Short Ratio4.73 Perf Half Y12.34%
Book/sh5.17 P/B8.79 EPS next Y9.27% ROA3.60% Target Price46.14 Perf Year16.91%
Cash/sh2.38 P/C19.06 EPS next 5Y16.00% ROE18.10% 52W Range35.30 - 45.69 Perf YTD19.59%
Dividend1.40 P/FCF- EPS past 5Y-3.60% ROI10.90% 52W High-0.68% Beta0.48
Dividend %3.08% Quick Ratio0.70 Sales past 5Y-3.10% Gross Margin80.30% 52W Low28.56% ATR0.73
Employees64400 Current Ratio0.90 Sales Q/Q13.00% Oper. Margin15.20% RSI (14)65.75 Volatility0.94% 1.37%
OptionableYes Debt/Eq1.45 EPS Q/Q-64.10% Profit Margin9.50% Rel Volume1.93 Prev Close45.42
ShortableYes LT Debt/Eq1.32 EarningsJul 25 BMO Payout161.60% Avg Volume3.02M Price45.38
Recom1.60 SMA202.89% SMA507.76% SMA20013.73% Volume3,478,477 Change-0.09%
Apr-02-19Downgrade UBS Neutral → Sell
Feb-05-19Initiated Exane BNP Paribas Outperform
Jan-25-19Upgrade Shore Capital Hold → Buy
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Mar-19-18Upgrade Jefferies Hold → Buy
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Feb-05-18Reiterated Bernstein Outperform $40 → $42
Jan-18-18Reiterated Leerink Partners Mkt Perform $33 → $36
Dec-29-17Upgrade JP Morgan Neutral → Overweight
Oct-16-17Upgrade Credit Suisse Neutral → Outperform
Sep-25-17Upgrade Exane BNP Paribas Neutral → Outperform
Sep-22-17Upgrade Bernstein Mkt Perform → Outperform
Sep-14-17Downgrade Liberum Buy → Hold
Sep-06-17Upgrade Natixis Bleichroeder Neutral → Buy
Aug-09-17Upgrade Investec Hold → Buy
Jul-28-17Downgrade Morgan Stanley Overweight → Equal-Weight
May-12-17Upgrade Credit Suisse Underperform → Neutral
Apr-10-17Downgrade Jefferies Buy → Hold
Aug-22-19 07:18AM  The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study Benzinga
Aug-21-19 10:50AM  AstraZeneca's Imfinzi Fails in Stage IV Lung Cancer Study Zacks
09:04AM  AstraZeneca's Drug Combo To Treat Non-Small Cell Lung Cancer Stumbles In Late-Stage Study Benzinga
07:35AM  UPDATE 2-AstraZeneca Imfinzi combination fails advanced lung cancer study Reuters
02:52AM  AstraZeneca faces setback in lung cancer drug trial Financial Times
Aug-20-19 11:01AM  China adds 148 drugs to key insurance list - state media Reuters
07:00AM  FARXIGA Met Primary Endpoint in Landmark Phase III DAPA-HF Trial for the Treatment of Patients With Heart Failure Business Wire
06:17AM  Sainsbury continues climb from 30-year low as FTSE 100 edges higher MarketWatch
05:34AM  Europe stocks stuck after two days of gains MarketWatch
04:15AM  UPDATE 2-European shares end lower as Italy's political crisis weighs Reuters
03:03AM  European shares rise for third straight session Reuters
Aug-16-19 11:28AM  Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY Zacks
10:33AM  AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL Zacks
09:00AM  Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC Zacks
Aug-15-19 10:30AM  Agios Rides High on Tibsovo Sales Amid Acute Competition Zacks
07:48AM  Merck's Cancer Immunotherapy Keytruda Continues to Aid Growth Zacks
Aug-14-19 08:15AM  3 Healthcare Stocks at All-Time Highs: Are They Buys? Motley Fool
08:00AM  CALQUENCE® (acalabrutinib) Granted US Breakthrough Therapy Designation for Chronic Lymphocytic Leukemia Business Wire
07:00AM  LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer Business Wire
Aug-13-19 10:58AM  AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis Benzinga
Aug-12-19 10:47AM  Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises Zacks
02:26AM  No-deal Brexit could deepen Europe's shortage of medicines - experts Reuters
Aug-09-19 11:29AM  AVEO Pharmaceuticals (AVEO) Q2 Earnings Beat, Revenues Lag Zacks
11:16AM  Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates Zacks
07:00AM  TAGRISSO® (OSIMERTINIB) Significantly Improves Overall Survival in the Phase III FLAURA Trial for 1st-line EGFR-mutated Non-small Cell Lung Cancer Business Wire
Aug-07-19 07:05AM  Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer GlobeNewswire
06:55AM  LYNPARZA® (Olaparib) Phase III Profound Trial in HRR* Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint Business Wire
Aug-06-19 04:37AM  The CEO Who Capped a $37 Billion Recovery With a Cancer Drug Deal Bloomberg
Aug-04-19 03:04PM  3 Lung Cancer Stocks That Could Soar in September Motley Fool
03:17AM  It Might Be Better To Avoid AstraZeneca PLC's (LON:AZN) Upcoming 1.0% Dividend Simply Wall St.
Jul-31-19 10:58AM  Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates Zacks
Jul-30-19 12:49PM  Merck (MRK) Beats on Q2 Earnings & Sales, Raises '19 View Zacks
Jul-29-19 04:18AM  Edited Transcript of AZN.L earnings conference call or presentation 25-Jul-19 11:00am GMT Thomson Reuters StreetEvents
Jul-27-19 12:20PM  10 Biggest Cancer-Fighting Stocks Motley Fool
Jul-26-19 08:58AM  AstraZeneca (AZN) Jumps: Stock Rises 5.7% Zacks
08:39AM  Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment Zacks
Jul-25-19 04:29PM  Why AstraZeneca, Ambev, and Nokia Jumped Today Motley Fool +5.72%
04:14PM  Two Pharma Stocks Flew On Strong Quarters But Drug Stocks Slipped Investor's Business Daily
01:06PM  Pharma giants eye 'period of change' as drug pricing talk heats up in DC Yahoo Finance
10:43AM  AstraZeneca Q2 results lifted by sales of new drugs Yahoo Finance Video
10:26AM  AstraZeneca (AZN) Q2 Earnings Top, '19 Product Sales View Up Zacks
09:00AM  Pharma Giants Top Second-Quarter Estimates, But Only One Stock Pops Investor's Business Daily
08:42AM  AstraZeneca climbs as it raises outlook on booming sales Financial Times
07:11AM  Miners and pharmaceutical giants inject life into London markets MarketWatch
06:26AM  AstraZeneca raises sales forecast after second quarter cancer drug, China boost Reuters
06:00AM  BioCardia Signs Exclusive Development Agreement With AstraZeneca GlobeNewswire
04:55AM  AstraZeneca `Open' to M&A as Sales Forecast Raised on New Cancer Treatments: CEO Bloomberg
03:56AM  Astra, Roche Join Rivals in Boosting Forecasts as New Drugs Prosper Bloomberg
Jul-24-19 10:53PM  Stocks to watch: AstraZeneca, Burford, Metro, Activision, Asos Financial Times
03:10AM  What Should We Expect From AstraZeneca PLC's (LON:AZN) Earnings In The Year Ahead? Simply Wall St.
Jul-22-19 10:27AM  Is AstraZeneca PLC's (LON:AZN) 19% ROE Better Than Average? Simply Wall St.
08:00AM  IMFINZI® (durvalumab) US Label Updated With Overall Survival Data in Unresectable, Stage III Non-small Cell Lung Cancer Business Wire
Jul-19-19 09:53AM  Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus Zacks
Jul-18-19 09:00AM  Edited Transcript of AZN.L earnings conference call or presentation 27-Jan-11 12:00pm GMT Thomson Reuters StreetEvents
Jul-17-19 11:20AM  Inovio (INO) Ends Some Early-Stage R&D Programs, Cuts Jobs Zacks
Jul-16-19 11:33PM  AstraZeneca to pay millions of pounds to former staff Financial Times
07:00PM  FOCUS-As steep patent cliff looms, Shionogi moves to develop its own U.S. sales staff Reuters
12:12PM  Philadelphia cell therapy startup adds Big Pharma veteran to its team American City Business Journals
09:36AM  Alkermes to Include Bipolar I Disorder in ALKS 3831 NDA Zacks
Jul-15-19 09:16PM  PRESS DIGEST- British Business - July 16 Reuters
05:43PM  AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes Zacks
04:44PM  Top Stock Reports for Cisco, Home Depot & Merck Zacks
07:00AM  AI Drug Hunters Could Give Big Pharma a Run for Its Money Bloomberg
03:07AM  UPDATE 1-AstraZeneca's Farxiga fails to get U.S. approval for Type-1 diabetes Reuters
02:31AM  RPT-AstraZeneca's Farxiga fails to get FDA approval for Type-1 diabetes Reuters
Jul-14-19 12:35AM  GSK to appoint Jonathan Symonds as chairman Financial Times
Jul-12-19 11:28AM  AstraZeneca's Imfinzi Gains Orphan Drug Status for SCLC Zacks
11:10AM  Why one top exec at this $105 billion drugmaker is 'very disappointed' with Trump Yahoo Finance
10:48AM  AstraZeneca weighs in on Trump's attack on big drug Yahoo Finance Video
09:30AM  AstraZeneca Outlines Drug Pipeline, Partnerships, Pricing Impacts TheStreet.com
Jul-11-19 09:50AM  Here's how you can find the prices of some popular drugs online Yahoo Finance
05:00AM  AstraZeneca takes lessons from fast food to serve China Financial Times
Jul-09-19 09:45AM  Intra-Cellular Therapies' Candidate Fails in Phase III Study Zacks
Jul-08-19 05:05PM  AVEO Pharmaceuticals Down More Than 50% YTD: Here's Why Zacks
Jul-05-19 09:32AM  Pharma Stock Roundup: PFE's Regulatory/Pipeline Updates, CHMP Nod for Several Drugs Zacks
Jul-03-19 01:54PM  Roche's Flu Medicine Xofluza Meets Goal in Study on Kids Zacks
Jul-02-19 02:34PM  GSK hikes price of subsidiary Tesaro's ovarian cancer drug American City Business Journals
09:01AM  AstraZeneca Gets CHMP Nod for Forxiga/Fasenra Expanded Label Zacks
Jun-30-19 03:13AM  What Did AstraZeneca PLC's (LON:AZN) CEO Take Home Last Year? Simply Wall St.
03:09AM  How Much Are AstraZeneca PLC (LON:AZN) Insiders Spending On Buying Shares? Simply Wall St.
Jun-28-19 05:08PM  AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study Zacks
Jun-27-19 08:56AM  IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer Business Wire
Jun-24-19 08:33AM  Pfizer's Talzenna Gets Approval in Europe for Breast Cancer Zacks
Jun-21-19 09:07AM  Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod Zacks
06:27AM  Investors Chronicle: Telecom Plus, International Consolidated Airlines, AstraZeneca Financial Times
Jun-20-19 09:18AM  AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod Zacks
Jun-19-19 05:21PM  Ironwood's Linzess Lowers Abdominal Symptoms in IBS-C Patients Zacks
Jun-18-19 08:59AM  AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use Zacks
03:05AM  AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment Reuters
03:02AM  UPDATE 1-AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment Reuters
02:35AM  AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment Reuters
Jun-17-19 09:51AM  AstraZeneca Gives Detailed Data From Calquence Leukemia Study Zacks
Jun-15-19 07:00AM  CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia Business Wire
Jun-14-19 06:00PM  Is AstraZeneca plc (AZN) A Good Stock To Buy? Insider Monkey
08:42AM  Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod Zacks
07:00AM  LOKELMA Demonstrated Efficacy in Treating Hyperkalemia in Patients with End-Stage Renal Disease on Hemodialysis Business Wire
Jun-13-19 04:12PM  Amgen, Biogen, Gilead and Novo Nordisk have very high capacity for M&A, says Moodys MarketWatch
09:31AM  Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock Zacks
Jun-10-19 09:57AM  The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca Zacks
08:00AM  FARXIGA Study Showed Reduced Progression of Kidney Disease or Renal Death in Patients with Type 2 Diabetes Business Wire
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a collaboration and license option agreement with Transgene SA for clinical development and commercialization of novel oncolytic immunotherapies. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ASTRAZENECA PLC10% OwnerOct 22Buy5.00600,0003,000,0003,004,554Oct 24 04:16 PM
ASTRAZENECA PLC10% OwnerSep 28Buy15.00246,6663,699,9902,164,855Oct 02 09:35 PM